Gibralt Capital Corporation is a Vancouver-based alternative asset manager with a global investment focus, particularly in North America. The firm's portfolio spans private equity, real estate, public market securities, and credit-oriented funds. Gibralt employs an opportunistic strategy targeting attractive absolute returns, often involving less liquid investments and varying correlations to traditional markets.

Strauss Zelnick, founder and managing partner of ZMC, serves as Chairman of Gibralt Capital. The firm's portfolio includes Epirus Biopharmaceuticals, which has raised $36 million. Gibralt has participated in Series B funding rounds, demonstrating its interest in supporting companies at growth stages. The firm's diverse investment approach and experienced leadership position it as a valuable partner for companies seeking capital and strategic guidance.